Jan 10, 2024
How to Write a Successful SBIR Proposal
In the current economic landscape, the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs have emerged as invaluable assets for small startups, particularly those in their nascent stages or with a focus on research endeavors. It provides a pathway for translating research ideas into viable commercial products and services. SBIR funding serves not only as a substantial financial boon but also opens doors to a supportive community. This community plays a pivotal role by assisting in the enrollment of future clinical application support, such as Medicare reimbursement, fostering peer networking opportunities, and paving the way for increased investments. In this monthly Salon, we have assembled an SBIR panel, including panelists from SBIR companies and an SBIR reviewer, to discuss a successful SBIR proposal application.
This event is Free !
This event is over.
Date and Time
January 10, 2024, 4:30 pm - 7:30 pmLocation
Denovo Biopharma, 10240 Science Center Drive, San Diego, CA 92121About this Event
Title: How to Write a Successful SBIR Proposal
Speaker: Ms. Pei Lin, CEO of Epigenome Technologies;
Dr. Fangyuan Tian, Associate Professor, California State University Long Beach
Dr. Andrew Wang, President of Ocean NanoTech LLC
Date: January 10 (Wednesday), 2024, 4:30-7:30 PM PT
Address: Denovo Biopharma, 10240 Science Center Drive, San Diego, CA 92121
Agenda:
16:30 Light dinner and social networking at onsite event
17:00 Introducing SABPA EPC, facility sponsor, and speaker
17:05 How to Write a Successful SBIR Proposal (Ms. Pei Lin, Dr. Fangyuan Tian, Dr. Andrew Wang )
18:00 Open discussion and social networking
19:30 Adjourn
ØFree food and drink will be provided.
ØOnsite venue limited to 50 participants on a first-come-first-serve basis.
ØRegistration required; Free of charge.
Øhttps://sabpa.org/member/event.php?id=100120
Speakers:
Ms. Pei Lin, CEO of Epigenome Technologies, has more than 20 years of industrial experience at prominent organizations such as Illumina, the Joint Genome Institute, and AstraZeneca. Epigenome’s focus is on advancing the development of innovative single-cell technologies, aiming to unravel the regulatory mechanisms underlying genetic diseases and oncogenesis. This endeavor involves identifying actionable biomarkers, creating companion diagnostics, and pinpointing potential drug targets, marking a significant stride in our commitment to advancing scientific understanding. Under her leadership, Epigenome Technologies received over $4M in SBIR/STTR funds, highlighting the significance of SBIR/STTR to small businesses. In this forthcoming presentation, she aims to delve into the transformative impact of SBIR/STTR on the trajectory of small businesses. Through the lens of Epigenome Technologies, she will explore how these programs contribute not only to financial backing but also to the overall development and growth of startups. By sharing insights from our journey of founding Epigenome Technologies alongside Dr. Bing Ren, they hope to illuminate the multifaceted support and opportunities that SBIR/STTR can provide, ultimately fostering an environment conducive to innovation, collaboration, and sustained cost balance for small businesses navigating the competitive landscape.
Dr. Fangyuan Tian is an Associate Professor in the Department of Chemistry & Biochemistry at California State University Long Beach. Born and raised in Jilin, China, she received her BS degree in Polymer Chemistry from Jilin University in 2008. She earned her Ph.D. in Analytical Chemistry from the University of Delaware and completed her postdoctoral work at the University of San Diego before joining CSULB in August 2015. She received tenure and was promoted to Associate Professor in 2021. She has received over $1M in funding from NIH and NSF as an independent PI. She has served on the NIH SBIR Biomaterials, Delivery, and Nanotechnology study section (BBBT-10) since 2021.
Dr. Andrew Wang is the president of Ocean NanoTech LLC with 20 years of SBIR experience and has won over 30 SBIR/STTR awards with more than $20 million in funding. He also serves on several NIH SBIR study sessions over 10 years in Cancer Diagnostics and Treatment, Radiation Therapy, Covid-19 Special Study Session, etc.
